Atlanta Consulting Group Advisors LLC Acquires 1,609 Shares of AbbVie Inc. $ABBV

Atlanta Consulting Group Advisors LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 103.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,167 shares of the company’s stock after purchasing an additional 1,609 shares during the period. Atlanta Consulting Group Advisors LLC’s holdings in AbbVie were worth $588,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Kaizen Financial Strategies boosted its holdings in shares of AbbVie by 3.9% during the 2nd quarter. Kaizen Financial Strategies now owns 4,362 shares of the company’s stock worth $810,000 after buying an additional 162 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of AbbVie by 4.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 269,019 shares of the company’s stock worth $49,935,000 after acquiring an additional 11,012 shares in the last quarter. Horrell Capital Management Inc. boosted its stake in shares of AbbVie by 36.7% in the 2nd quarter. Horrell Capital Management Inc. now owns 410 shares of the company’s stock worth $76,000 after buying an additional 110 shares during the last quarter. Bailard Inc. raised its stake in shares of AbbVie by 66.4% during the 2nd quarter. Bailard Inc. now owns 29,304 shares of the company’s stock worth $5,439,000 after purchasing an additional 11,693 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after acquiring an additional 924,761 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 3.7%

Shares of NYSE ABBV opened at $233.42 on Thursday. The stock has a market capitalization of $412.54 billion, a price-to-earnings ratio of 111.15, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The firm’s 50-day moving average price is $224.10 and its 200-day moving average price is $203.43. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ABBV. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Citigroup cut their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Wells Fargo & Company upped their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $236.57.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.